Cysteine cathepsins and cystatins as cancer biomarkers

The Cancer Degradome: Proteases and Cancer Biology

Volumn , Issue , 2008, Pages 587-625

  Lah, Tamara T ^a   Obermajer, Nataša ^b   Alonso, María Beatriz Durán ^a   Kos, Janko ^b  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900271528     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69057-5_29     Document Type: Chapter

References (168)

1. Abrahamson M., Barrett A.J., Salvesen G., et al. (1986). Isolation of cysteine proteinase inhibitors from human urine. Their physiological and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 261:11282-11289
2. Abrahamson M., Alvarez-Fernandez M., Nathanson C.M. (2003). Cystatins. Biochem. Soc. Symp. 70:179-199
3. Acuff H.B., Sinnamon M., Fingleton B., et al. (2006). Analysis of host- and tumour-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 66:7968-7975
4. Aho H.J., Ping W., Soderstrom K.O., et al. (1995). Acid cysteine proteinase inhibitor in cutanus lymphocytic infiltrates. Am. J. Dermatopathol. 17:115-125
5. Alvarez-Fernandez M., Barrett A.J., Gerhartz B., et al. (1999). Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 274:19195-19203
6. Arora S., and Chauhan S.S. (2002). Identification and characterization of a novel human cathepsin L splice variant. Gene 293:123-131
7. Barrett A.J., Rawlings N.D., Woessner J.F. (2004). The Handbook of Proteolytic Enzymes, 2nd ed. Academic Press. London.
8. Bell-McGuinn K.M., Garfall A.L., Bogyo M., et al. (2007). Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumour growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67:7378-7385
9. Berdowska I. (2004). Cysteine proteases as disease markers. Clin. Chim. Acta 342:41-69
10. Bianchi F., Hu J., Pelos S.G., et al. (2004). Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analysed by cDNA microarray. Clin. Cancer Res. 10:6023-6028
11. Blaveri E., Simko J.P., Korkola J.E., et al. (2005). Bladder cancer outcome and subtype classification. Clin. Cancer Res. 11:4044-4056
12. Brubaker K.D., Vessella R.L., True L.D., et al. (2003). Cathepsin K mRNA and protein expression in prostate cancer progression. J. Bone Miner. Res. 18:220-230
13. Budihna M., Strojan P., Smid L., et al. (1996). Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe Seyler 377:385-390
14. Buhling F., Waldburg N., Gerbe A., et al. (2000). Cathepsin K expression in human lung. Adv. Exp. Med. Biol. 477:281-286
15. Calkins C.C., Sameni M., Koblinski J., et al. (1998). Differential localization of cysteine proteinase inhibitors and target cysteine protease, cathepsin B by immuno-confocal microscopy. J. Histochem. Cytochem. 46:745-751
16. Campo E., Munoz J., Miguel R., et al. (1994). Cathepsin B expression in colorectal carcinomas correlates with tumour progression and shortened patiet survival. Am. J. Pathol. 145:310-319
17. Caserman S., Kenig S., Sloane B.F., et al. (2006). Cathepsin L splice variants in human breast cell lines. Biol. Chem. 387:629-634
18. Cavallo-Medved D., Dosescu J., Linebaugh B.E., et al. (2003). Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 5:1-12
19. Chu J.H., Sun Z.Y., Meng X.L., et al. (2006). Differential metastasis-associated gene analysis of prostate carcinoma cell derived from primary tumour and spontaneous lymphatic metastasis in nude mice with orthotopic implantantion of PC-3M cells. Cancer Lett. 233:70-88
20. de Re E.C., Shuja S., Cai J., et al. (2000). Alterations in cathepsin H activity and protein pattern in human colorectal carcinoma. Br. J. Cancer 82:1317-1326
21. Dreilich M., Wagenius G., Bergstrom S., et al. (2005). The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma. Med. Oncol. 22:29-38
22. Ebert W., Knoch H., Werle B., et al. (1994). Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res. 14:895-900
23. Ebert E., Werle B., Julke B., et al. (1997). Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumour tissue. Adv. Exp. Med. Biol. 421:259-265
24. Eide T.J., Jarvinen M., Hopsu-Havu V.K., et al. (1997). Immunolocalization of cystatin A in neoplastic, virus and inflammatory lesions of the uterine cervix. Acta Histochem. 93:241-248
25. Eijan A.M., Casabe A.B., Puricelli L., et al. (1997). Levels of plasma cysteine-proteinase activity in bladder cancer patients. Oncol. Rep. 4:447-450
26. Eijan A.M., Sandes E.O., Puricelli L., et al. (2000). Cathepsin B levels in urine from bladder cancer patients. Oncol. Rep. 7:1395-1399
27. Eijan A.M., Sandes E.O., Riveros M.D., et al. (2003). High expression of cathepsin B in transitional bladder carcinoma correlates with tumour invasion. Cancer 98:262-268
28. Fernandez P.L., Farre X., Nadal A., et al. (2001). Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 95:51-55
29. Flannery T., Gibson D., Mirakhur M., et al. (2003). The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 163:175-182
30. Flannery T., McQuaid S., McGoohan C., et al. (2006). Cathepsin S expression: An independent prognostic factor in glioblastoma tumours-A pilot study. Int. J. Cancer 119:854-860
31. Flannery T., McConnell R.S., McQuaid S., et al. (2007). Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo. Br. J. Neurosurg. 21:204-209
32. Foekens J.A., Kos J., Peters H.A., et al. (1998). Prognostic significance of cathepsin B and L in primary human breast cancer. J. Clin. Oncol. 16:1013-1021
33. Friedl P., and Wolf K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 3:362-374
34. Froelich E., Schlagenhauff B., Mohrle M., et al. (2001). Activity, expression and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 91:972-982
35. Garcea G., Neal C.P., Pattenden C.J., et al. (2005). Molecular prognostic markers in pancreatic cancer: A systemic review. Eur. J. Cancer 41:2213-2236
36. Gochareva V., and Joyce J.A. (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60-64
37. Gochareva V., Zeng W., Ke D., et al. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20:543-556
38. Goldman T., Suler L., Ribbert D., et al. (1999). The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. Pathol. Res. Pract. 195:171-175
39. Gondi C.S., Lakka S.S., Dinh D.H., et al. (2004). RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23:8486-8496
40. Gutman S., and Kessler L.G.F. (2006). The US Food and drug administration perspective on cancer biomarker development. Nat. Rev. Cancer 6:565-571
41. Harbeck N., Alt U., Krueger A., et al. (2001). Prognostic impact of proteolytic factors (urokinasetype plasminogen activator, plasminogen activator inhibitor 1 and cathepsins B, D and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin. Cancer Res. 7:2757-2764
42. Harbeck N., Kates R.E., Look M.P., et al. (2002). Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n 3424). Cancer Res. 62:4617-4622
43. Hazen L.G., Bleeker F.E., Lauritzen B., et al. (2000). Comparative localisation of cathepsin B protein and activity in colorectal cancer. J. Histochem. Cytochem. 48:1421-1430
44. Herszenyl L., Plebani M., Carraro P., et al. (1999). The role of cysteine and serine proteases in colorectal carcinoma. Cancer 86:1135-1142
45. Hirai K., Yokoyama M., Asano G., et al. (1999). Expression of cathepsin B and cystatin C in human colorectal cancer. Hum. Pathol. 30:680-688
46. Honey K., and Rudensky A.Y. (2003). Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3:472-482
47. Hughes S.J., Glover T.W., Zhu X.-X. et al. (1998). A novel amplification at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Nat. Acad. Soc. USA 95:12410-12415
48. Jedeszko C., and Sloane B.F. (2004). Cysteine cathepsins in human cancer. Biol. Chem. 385:1017-1027
49. Jiborn T., Abrahamson M., Wallin H., et al. (2004). Cystatin C is highly expressed in human male reproductive system. J. Androl. 25:564-572
50. Joyce J.A., and Hanahan D. (2004). Multiple roles for cysteine cathepsins in cancer. Cell cycle 3:1516-1519
51. Joyce J.A., Baruch A., Chehade Kmeyer-Morse N., et al. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443-453
52. Kageshita T., Yoshii A., Kimura T., et al. (1995). Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch. Dermatol. Res. 287:266-272
53. Karkola J.E., DeVries S., Fridlyan J., et al. (2003). Differentiation of lobular versus ductal breast carcinoma by expression microarray analysis. Cancer Res. 63:7167-7175
54. Kastelic L., Turk B., Kopitar-Jerala N., et al. (1994). Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett. 82:81-88
55. Kawasaki G., Kato Y., Mizuno Y.A., et al. (2002). Cathepsins expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 93:446-454
56. Kayser K., Richter N., Hufnage P., et al. (2003). Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer. Anticancer Res. 23:2767-2772
57. Kos J., and Lah T.T. (1998). Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol. Rep. 5:1349-1361
58. Kos J., and Lah T.T. (2006). Cystatins in cancer. In: Human Stefins and Cystatins, eds. E. Zerovnik, N. Kopitar-Jerala. pp. 152-165 New York: Nova Science Publishers, Inc.
59. Kos J., Ŝmid A., Kraŝovec M., et al. (1995). Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler 376:401-405
60. Kos J.,Ŝtabuc B., Schweiger A., et al. (1997). Cathepsins B, H and L and their inhibitors in stefin A and cystatin C in sera of melanoma patients. Clin. Cancer Res. 3:1815-1822
61. Kos J., Nielsen H.-J., Kraŝovec M., et al. (1998). Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin. Cancer Res. 4:1511-1516
62. Kos J., Kraŝovec M., Cimerman N., et al. (2000). Cysteine protease inhibitors stefin A, stefin B and cystatin C in sera from patients with colorectal cancer: Relation to prognosis. Clin. Cancer Res. 6:505-511
63. Kos J., Sekirnik A., Kopitar G., et al. (2001). Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: Relation to prognosis. Br. J. Cancer 85:1193-1200
64. Krepela E., Prochazka J., Karova B., et al. (1998). Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma 45:318-331
65. Kuopio T., Kankaanranta A., Jalava P., et al. (1998). Cysteine protease inhibitor cystatin A in breast cancer. Cancer Res. 58:432-436
66. Lah T.T., and Kos J. (1998). Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379:125-130
67. Lah T.T., Kokalj-Kunovar M., Kastelic L., et al. (1991). Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett. 61:243-253
68. Lah T.T., Kokalj-Kunovar M.,Ŝtrukelj B., et al. (1992). Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer 50:36-44
69. Lah T.T., Kos J., Blejec A., et al. (1997). The expression of lysosomal proteases and their inhibitors in breast cancer: Possible relationship to prognosis of the disease. Pathol. Oncol. Res. 3(2):89-99
70. Lah T.T., Kalman E., Najjar D., et al. (2000a). Cells producing cathepsins D, B and L in human breast carcinoma and their association with prognosis. Hum. Pathol. 31:149-160
71. Lah T.T.,Ĉerĉek M., Blejec A., et al. (2000b). Cathepsin B, a prognostic indicator in lymph nodenegative breast carcinoma patients: Comparison with cathepsin D, cathepsin L and other clinical indicators. Clin. Cancer Res. 6:578-584
72. Lah T.T., Dura? Alonso M.B., and Van Noorden C.J.V. (2006). Antiprotease therapy in cancer: Hot or not? Expert Opin. Biol. Ther. 6:257-279
73. Lah T.T., Nanni I., Trinkaus M., et al. (2008). Towards better diagnosis and prognosis of aggressive meningioma: A role of cysteine proteases. (submitted)
74. Lakka S.S., Gondi C.S., Yanamandra N., et al. (2004). Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23:4681-4689
75. Ledakis P., Tester W., Rosenberg N., et al. (1996). Cathepsins D, B and L in malignant human lung tissue. Clin. Cancer Res. 5:561-568
76. Leinonen T., Pirinen R., Bohm J., et al. (2007). Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J. Clin. Pathol. 60:515-519
77. Leto G., Tumminello F.M., Pizzolanti G., et al. (1997). Lysosomal cathepsins B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: Potential clinical implications. Oncology 54:79-83
78. Leviĉar N., Kos J., Blejec A., et al. (2002). Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen-activator inhibitor-1 and clinico-pathological data of breast cancer patients. Cancer Detect. Prev. 26:42-49
79. Li W., Ding F., Zhang L., et al. (2005). Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibit tumour cell growth, angiogenesis, invasion and metastasis. Clin. Cancer Res. 11:8753-8762
80. Liaudet-Coopman E., Beaujouin M., Derocq D., et al. (2006). Cathepsin D: A newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 237:167-179
81. Lignelid H., Collins V.P., Jacobsson B. (1997). Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol. (Berl) 93:494-500
82. Linnerth N.M., Sitbovan K., Moorehead R.A. (2005). Use of a transgenic model to identify markers of human lung tumours. Int. J. Cancer 114:977-982
83. Luo A., Kong J., Hu G., et al. (2004). Discovery of Ca(2)-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 23:1291-1299
84. Macabeo-Ong M., Shiboski C.H., Silerman S., et al. (2003). Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression. Oral. Oncol. 39:638-647
85. Mason R.W., Gal S., Gottesman M.M. (1987). The identification of the major excreted protein (MEP) from a transformed mouse fibroblasts cell line as a catalytically active precursor form of cathepsin L. Biochem. J. 248:449-454
86. Mikkelsen T., Yan P.S., Ho K.L., et al. (1995). Immunolocalization of cathepsin B in human glioma: Implications for tumor invasion and angiogenesis. J. Neurosurg. 83:285-290
87. Mirtti T., Alanen K., Kallajoki M. et al. (2003). Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate 54:290-298
88. Mohamed M.M., and Sloane B.F. (2006). Cysteine cathepsins: Multifunctional enzymes in cancer. Nat. Rev. Cancer 6:764-775
89. Muentener K., Zwicky R., Scus G., et al. (2003). The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochem. Cell Biol. 119:93-101
90. Mulaomerovic A., Halilbaŝic?A., Ĉiĉkuŝic?E., et al. (2007). Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett. 248:192-197
91. Naegler D.K., Hrueger S., Kellner A., et al. (2004). Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 60:109-119
92. Nagai A., Terashim M., Harada T., et al. (2003). Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin. Chim. Acta 329:53-60
93. Nakabayashi H., Hara M., Shimuzu K. (2005). Clinicopathologic significance of cystatin C expression in gliomas. Hum. Pathol. 36:1008-1015
94. Niedergethmann M., Wostbrock B., Sturm J.W., et al. (2004). Prognostc impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2:204-211
95. Niewczas M., Paczek L., Krawczyk M., et al. (2002). Enzymatic activities of cathepsin B, cathepsin B and L, plasmin, trypisn and colagenase in hepatocellular carcinoma. Pol. Arch. Med. Wewn. 108:653-662
96. Nishida Y., Kohno K., Kawamata T., Morimotsu K., Kuwano M., Miyakawa I. (1995). Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol. Oncol. 56:357-361
97. Nishikawa H., Ozaki Y., Nakanishi T., et al. (2004). The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol. Oncol. 92:881-886
98. Obermajer N., Doljak B., Kos J. (2006). Cysteine cathepsins: Regulators of antitumour immune response. Expert Opin. Biol. Ther. 6:1295-1309
99. Overall C.M., and Loez-Ot C. (2002). Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2:657-672
100. Palungwachira P., Kakuta M., Yamazaki M., et al. (2002). Immunohistochemical localization of cathepsin L and cystatin A in normal skin and skin tumors. J. Dermatol. 29:573-579
101. Parker B.S., Bidwell B.N., Slavin J.L., et al. (2007). Enhanced expression of the cathepsin inhibitor stefin A is associated with metastasis in breast cancer. Clin. Exp. Metastasis 24:211-316
102. Petty R.D., Kerr K.M., Murray G.I., et al. (2006). Tumour transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small cell lung cancer. J. Clin. Oncol. 24:1729-1744
103. Pollanen R., Pyykkonen K., Jarvinen M., et al. (1995). Immunolocalization of cystatin A in condylomatous and dysplastic lesions of the human uterine cervix: Correlation with the presence and type of human papillomavirus infection. Int. J. Ginecol. Pathol. 14:217-222
104. Poteriaeva O.N., Usova T.A., Levina O.A., et al. (2003). Immunoenzyme technique for analysis of cystatin C in serum of patients with hemoblastosis. Klin. Lab. Diagn. 7:35-38
105. Rempel S.A., Rosenblum M.L., Mikkelsen T., et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54:6027-6031
106. Roesch-Ely M., Nees M., Karsai S., et al. (2007). Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26:54-64
107. Russo A., Bazan V., Gebbia N., et al. (1995). Flow cytometry DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Cancer (Phila) 76:1757-1764
108. Saleh Y., Sebzda T., Warwas M., et al. (2005). Expression of cystatin M in clinical human colorectal cancer tissues. J. Exp. Theor. Oncol. 5:49-53
109. Saleh Y., Wnukiewicz J., Andrzejak R., et al. (2006). Cathepsin B and cysteine protease inhibitors in human tongue cancer: Correlation with tumour staging and in vitro inhibition of cathepsin B by chicken cystatins. J. Cancer Mol. 2:67-72
110. Schmitt M., Jaenicke F., Graeff H. (1992). Protease, matrix degradation and tumour-cell spread. Fibrinolysis 6:1-17
111. Schweiger A., Christensen I.J., Nielsen H.J., et al. (2004). Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int. J. Biol. Markers 19:254-257
112. Scorilas A., Fotiou S., Tsiambas E., et al. (2002). Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol. Chem. 383:1297-1303
113. Shi G.P., Sukhova G.K., Kuzuya M., et al. (2003). Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92:493-500
114. Shiraishi T., Mori M., Tanaka S., et al. (1998). Identification of cystatin B in human esophageal carcinoma, using differential displays in which gene expression is related to lymph node metastasis. Int. J. Cancer 79:175-178
115. Shuja S., Sheahan K., Murnane M.J. (1991). Cysteine endopeptidase activity levels in normal human tumours, colorectal adenoma and carcinoma. Int. J. Cancer 49:341-346
116. Sinha A.A., Gleason D.F., DeLeon O.F., et al. (1993). Localisation of a biotonylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat. Rec. 235:233-240
117. Sinha A.A., Quast B.J., Wilson M.J., et al. (2001). Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 48:274-284
118. Sinha A.A., Quast B.J., Wilson M.J., et al. (2002). Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94:3141-3149
119. Sinha A.A., Morgan J.L., Wood N., et al. (2007). Heterogeneity of cathepsin B and stefin A expression in Gleason pattern 3 3 (score 6) prostate cancer needle biopsies. Anticancer Res. 27:1407-1413
120. Sivaparvathi M., Sawaya R., Wang S.W., et al. (1995). Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metastasis 13:49-56
121. Sivaparvathi M., Sawaya R., Gokaslan Z.L., et al. (1996a). Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Lett. 104:121-126
122. Sivaparvathi M., Yamamoto M., Nicolson G.L. et al. (1996b). Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin. Exp. Metastasis 14:27-34
123. Sloane B.F., Moin K., Lah T.T. (1994). Lysosomal enzymes and their endogenous inhibitors in neoplasia. In: Biochemical and molecular aspects of selected cancers, eds. T.G. Pretlow, T.P. Pretlow. pp. 411-466 New York: Academic Press.
124. Soderstrom K.O., Laato M., Wu P., et al. (1995). Expression of acid cysteine protease inhibitor (ACPI) in normal human prostate, benign prostatic hyperplasia and adenocarcinoma. Int. J. Cancer 62:1-4
125. Sotiropoulou G., Anisowitz A., Sager R. (1997). Identification, cloning and characterisation of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. Cancer Res. 272:903-910
126. Staak A., Tolic D., Kristiansen G., et al. (2004). Expression of cathepsins B, H and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 63:1089-1094
127. Strojan P., Budihna M., Ŝmid L., et al. (2000). Prognostic significance of cysteine proteases cathepsin B and L and their endogenous inhibitor stefins A and B in patients with squamous cell carcinoma with head and neck cancer. Clin. Cancer Res. 6:1052-1062
128. Strojan P., Budihna L.,Ŝmid L., et al. (2001). Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell cacinoma of head and neck. Neoplasma 48:66-71
129. Strojan P., Svetic B., Ŝmid L., et al. (2004a). Serum cystatin C in patients with head and neck carcinoma. Clin. Chem. Acta 344:155-161
130. Strojan P., Oblak I., Svetic B., et al. (2004b). Cystaine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: Relation to prognosis. Br. J. Cancer 90:1961-1968
131. Strojan P., Anicin A., Svetic B., et al. (2007). Stefin A and stefin B: Markers for prognosis in operable squamous cell carcinoma of head and neck. Int. J. Radiat. Oncol. Biol. Phys. 68:1335-1341
132. Strojnik T., Kos J., Zidanik B., et al. (1999). Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. 5:559-567
133. Strojnik T., Zajc I., Bervar A., et al. (2000). Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch. 439:R122-R123
134. Strojnik T.,Ẑidanik B., Kos J., et al. 2001 Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 48 598-605
135. Strojnik T., Kavalar R., Trinkaus M., et al. (2005). Cathepsin L in glioma progression: Comparison with cathepsin B. Cancer Detect. Prev. 29:448-455
136. Takeuchi M., Fukuda Y., Nakano I., et al. (2001). Elevation of cystatin C concentrations in patients with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 13:951-955
137. Talieri M., Papdopoulu S., Scorilas A., et al. (2004). Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett. 205:97-106
138. Terada T., Ohta T., Minato H., Nakanuma Y. (1995). Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum. Pathol. 26:746-752
139. Thomssen C., Schmitt M., Goretzki L., et al. (1995). Prognostic value of the cysteine proteases cathepsins B and L in human breast cancer. Clin. Cancer Res. 1:741-746
140. Thomssen C., Oppelt P., Jaenicke F., et al. (1998). Identification of low risk node-negative breast cancer patients by tumour biological factors PAI-1 and cathepsin L. Anticancer Res. 18:2173-2180
141. Tokyol C., Koken T., Demirbas M., et al. (2006). Expression of cathepsin D in bladder carcinoma: Correlation with biological features and serum cystatin C levels. Tumori 92:230-235
142. Trinkaus M., Vraniĉ A., Dolenc V.V., et al. (2003). Cathepsin L in human meningiomas. Radiol. Oncol. 37:89-99
143. Trinkaus M., Vraniĉ A., Dolenc V.V., et al. (2005). Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningioma. Int. J. Biol. Markers 20:50-59
144. Troy A.M., Sheahan K., Mulcahy H.E., et al. (2004). Expression of cathepsins B and L antigen and activity is associated with early colorectal cancer progression. Eur. J. Cancer 40:1610-1616
145. Turk B. (2006). Targeting proteases: Successes, failures and future prospects. Nat. Rev. Drug Discov. 5:785-799
146. Ulmer A., Korber V., Schmid H., et al. (1998). Increased activity of cathepsin B in fibroblasts isolated from primary melanoma in comparison to fibroblasts from normal skin. Exp. Dermatol. 7:14-17
147. Vazquez-Otrin G., Pina-Sanchez P., Vazquez K. et al. (2005). Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 5:1-11
148. Vigneswaran N., Zhao W., Dassanayake A., et al. (2000). Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum. Pathol. 31:931-937
149. Vigneswaran N., Wu J., Muller S., et al. (2005). Expression analysis of cystatin C and M in lasercapture microdissectioned human breast cancer cells-A preliminary study. Pathol. Res. Pract. 200:753-762
150. Visscher D.W., Sloane B.F., Sameni M., et al. (1994). Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod. Pathol. 7:76-81
151. Waghray A., Keppler D., Sloane B.F., et al. (2002). Identification of a truncated form of human prostate tumour cells. J. Biol. Chem. 277:11533-11538
152. Wang M., Tang J., Liu S., et al. (2005). Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J. Neurooncol. 71:3-7
153. Wang B., Sun J., Kitamoto S., et al. (2006). Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 281:6020-6029
154. Warwas M., Haczynska H., Gerber J., et al. (1997). Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem. 35:301-304
155. Warwas M., Gerber J., Haczynska H., et al. (2000). Comparison of cathepsin B-like activity with CA125 assays use in ovarian cancer diagnostic. Ginekol. Pol. 71:400-405
156. Werle B., Ebert W., Klein W., et al. (1995). Assessment of cathepsin L activity by use of the inhibitor Ca-074 compared to cathepsin B activity in human lung tumour tissue. Biol. Chem. Hoppe-Seyler 376:157-164
157. Werle B., Juelke B., Lah T., et al. (1997). Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br. J. Cancer 75:1137-1143
158. Werle B., Kraft C., Kos J., et al. (2000). Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non-small cell lung carcinoma. Cancer 89:2282-2289
159. Werle B., Sauckel K., Nathanson C.M., et al. (2003). Cystatin C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol. Chem. 384:281-287
160. Werle B., Kotzsch M., Lah T.T., et al. (2004). Cathepsin B, plasminogen activator-inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non small cell lung cancer. Anticancer Res. 24:4147-4162
161. Werle B., Schanzerbacher U., Lah T.T., et al. (2006). Cystatins in non-small cell lung cancer: Tissue levels, localization and relation to prognosis. Oncol. Rep. 16:647-656
162. Wild P.J., Herr A., Wissmann C., et al. (2005). Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin. Cancer Res. 11:4415-4429
163. Yan S., and Sloane B.F. (2003). Molecular regulation of human cathepsins B implication in pathologies. Biol. Chem. 384:845-854
164. Yano M., Hirai K., Naito Z., et al. (2001). Expression of cathepsin B and cystatin C in human breast cancer. Surg. Today 31:385-391
165. Yoshii A., Kageshita T., Tsushima H., et al. (1995). Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in metastatic tumours. Arch Dermatol. Res. 287:209-213
166. Zajc I., Bervar A., Lah T.T. (2006). Cysteine cathepsins, stefins and extracellular matrix degradation during invasion of transformed human breast cancer cell lines. Radiol. Oncol. 40:259-271
167. Zhang J., Shridhar J., Dai Q., et al. (2004). Cystatin M: A novel tumour suppressor gene for breast cancer. Cancer Res. 64:6957-6964
168. Zore I., Kraŝovec M., Cimerman N., et al. (2001). Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol. Chem. 382:805-810.